Literature DB >> 28781373

Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.

Volker Vallon1, Scott C Thomson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28781373     DOI： 10.1038/nrneph.2017.113

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Diabetologia       Date:  2016-11-22       Impact factor: 10.122

Review 2.  The renal hemodynamic basis of diabetic nephropathy.

Authors:  G T O'Bryan; T H Hostetter
Journal:  Semin Nephrol       Date:  1997-03       Impact factor: 5.299

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 4.  Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Authors:  Steven G Coca; Faramarz Ismail-Beigi; Nowreen Haq; Harlan M Krumholz; Chirag R Parikh
Journal:  Arch Intern Med       Date:  2012-05-28

Review 5.  Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Annu Rev Physiol       Date:  2012       Impact factor: 19.318

6.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

7.  Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.

Authors:  Kamlesh Khunti; Melanie Davies; Azeem Majeed; Brian Larsen Thorsted; Michael Lyng Wolden; Sanjoy K Paul
Journal:  Diabetes Care       Date:  2014-12-09       Impact factor: 19.112

8.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

9.  Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.

Authors:  Sunder Mudaliar; Sindura Alloju; Robert R Henry
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112

10.  CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

Authors:  Ele Ferrannini; Michael Mark; Eric Mayoux
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112
  10 in total
  5 in total

Review 1.  Role of TRPC6 in Progression of Diabetic Kidney Disease.

Authors:  Alexander Staruschenko; Denisha Spires; Oleg Palygin
Journal:  Curr Hypertens Rep       Date:  2019-05-21       Impact factor: 5.369

Review 2.  The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.

Authors:  Hadi Fattah; Volker Vallon
Journal:  Drugs       Date:  2018-05       Impact factor: 9.546

3.  Postprandial Effects on ENaC-Mediated Sodium Absorption.

Authors:  Gregory Blass; Christine A Klemens; Michael W Brands; Oleg Palygin; Alexander Staruschenko
Journal:  Sci Rep       Date:  2019-03-12       Impact factor: 4.996

4.  How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.

Authors:  Silvia Canivell; Manel Mata-Cases; Bogdan Vlacho; Mònica Gratacòs; Jordi Real; Dídac Mauricio; Josep Franch-Nadal
Journal:  J Diabetes Res       Date:  2019-11-11       Impact factor: 4.011

5.  Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.

Authors:  Koki Chiba; Hiroshi Nomoto; Akinobu Nakamura; Kyu Yong Cho; Kumiko Yamashita; Yui Shibayama; Aika Miya; Hiraku Kameda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
Journal:  J Diabetes Investig       Date:  2020-08-02       Impact factor: 4.232
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.